SSA
TEVA icon

Schonfeld Strategic Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-250,000
Closed -$1.88M – 3160
2022
Q2 		$1.88M Buy
+250,000
New +$2.18M 0.02% 764

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Schonfeld Strategic Advisors's TEVA Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 37,209 shares — an estimated $624K sold.

Schonfeld Strategic Advisors first reported a position in TEVA in Q1 2016 and held it in 28 quarters. The position peaked at $21.3M in Q4 2022. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 37,209 Teva Pharmaceuticals shares in Q3 2025, an estimated $624K.
  • Schonfeld Strategic Advisors first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 28 quarters.
  • Schonfeld Strategic Advisors's Teva Pharmaceuticals position peaked at $21.3M in Q4 2022.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.